Mutations

SORL1 N1392N

Overview

Clinical Phenotype: Alzheimer's Disease
Position: (GRCh38/hg38):Chr11:121590137 C>T
Position: (GRCh37/hg19):Chr11:121460846 C>T
dbSNP ID: rs2276412
Coding/Non-Coding: Coding
DNA Change: Substitution
Expected Protein Consequence: Silent
Codon Change: AAC to AAT
Reference Isoform: SORL1 Isoform 1 (2214 aa)
Genomic Region: Exon 30

Findings

This synonymous variant was reported to associate with Alzheimer’s disease in two studies with several thousand cases and controls— a case-control study from the Alzheimer's Disease Genetics Consortium (Reitz et al., 2013) and two meta-analyses of data from the International Genetics of Alzheimer’s Project (Liu et al., 2017; NIAGADS GWAS: Alzheimer's Disease). No association was reported in a smaller European cohort composed of 1255 AD cases and 1938 controls (Verheijen, et al., 2016).

The variant was not associated with MRI markers of brain atrophy or cerebrovascular disease (white matter hyperintensities) in African-American or white participants in the family-based MIRAGE study (Cuenco et al., 2009).

The N1392N variant is classified as likely benign by the criteria of Holstege and colleagues (Holstege et al., 2017).

Functional Consequences

The variant was predicted to be tolerated by SIFT and neutral by PROVEAN, and it was classified as a polymorphism by Mutation Taster (El Bitar et al., 2019).

Table

Risk Allele(s) N
Cases | Controls
aAllele frequency
Cases | Controls
Reported association measurements Ancestry
(Cohort)
Reference
Large-scale studies and meta-analyses
T 17008 | 37154   p = 4.68×10-7 European
(IGAP, stage 1)
Liu et al., 2017
(GWAS)
T 25580 | 48466   p = 3.50×10-8 European
(IGAP, stages 1 and 2)
NIAGADS GWAS:
Alzheimer's Disease
T 11840 | 10931   p = 2.64×10-6 Caucasian
(Alzheimer's Disease Genetics Consortium)
Reitz et al., 2013
T 1255 | 1938 0.02 | 0.02 OR = 0.76
[CI: 0.48-1.18]
p = 0.22
European
(European Early-Onset Dementia Consortium)
Verheijen et al., 2016
(meta-analysis)
Other studies
T 117 | 0 0.171 | N.A.   Saudi Arabian
(King Faisal Specialist Hospital & Research Center)
El Bitar et al., 2019
T 640 | 1268 0.025 | 0.024   Dutch
(Rotterdam Study, Amsterdam Dementia Cohort, Alzheimer Centrum Zuidwest Nederland (ACZN), 100-plus Study)
Holstege et al., 2017

aAllele frequencies as reported by study authors or calculated by Alzforum curators from data provided in the study, assuming heterozygosity if not explicitly stated in the paper.

This table is meant to convey the range of results reported in the literature. As specific analyses, including co-variates, differ among studies, this information is not intended to be used for quantitative comparisons, and readers are encouraged to refer to the original papers. Thresholds for statistical significance were defined by the authors of each study. (Significant results are in bold.) Note that data from some cohorts may have contributed to multiple studies, so each row does not necessarily represent an independent dataset. While every effort was made to be accurate, readers should confirm any values that are critical for their applications.

Last Updated: 18 Jul 2024

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

References

Paper Citations

  1. . Independent and epistatic effects of variants in VPS10-d receptors on Alzheimer disease risk and processing of the amyloid precursor protein (APP). Transl Psychiatry. 2013;3:e256. PubMed.
  2. . SORL1 Variants Show Different Association with Early-Onset and Late-Onset Alzheimer's Disease Risk. J Alzheimers Dis. 2017;58(4):1121-1128. PubMed.
  3. . A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer's disease. Acta Neuropathol. 2016 Aug;132(2):213-24. Epub 2016 Mar 30 PubMed.
  4. . Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease. Arch Neurol. 2008 Dec;65(12):1640-8. PubMed.
  5. . Characterization of pathogenic SORL1 genetic variants for association with Alzheimer's disease: a clinical interpretation strategy. Eur J Hum Genet. 2017 Aug;25(8):973-981. Epub 2017 May 24 PubMed.
  6. . Genetic Study of Alzheimer's Disease in Saudi Population. J Alzheimers Dis. 2019;67(1):231-242. PubMed.

External Citations

  1. NIAGADS GWAS: Alzheimer's Disease
  2. NIAGADS GWAS: Alzheimer's Disease

Further Reading

No Available Further Reading

Protein Diagram

Primary Papers

  1. . Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease. Arch Neurol. 2008 Dec;65(12):1640-8. PubMed.

Other mutations at this position

External Resources

Disclaimer: Alzforum does not provide medical advice. The Content is for informational, educational, research and reference purposes only and is not intended to substitute for professional medical advice, diagnosis or treatment. Always seek advice from a qualified physician or health care professional about any medical concern, and do not disregard professional medical advice because of anything you may read on Alzforum.